US 11,667,696 B2
Selective reduction of proteins
Damon L. Meyer, Bellevue, WA (US)
Assigned to Seagen Inc., Bothell, WA (US)
Filed by Seagen Inc., Bothell, WA (US)
Filed on Sep. 24, 2019, as Appl. No. 16/580,290.
Application 16/580,290 is a division of application No. 15/117,254, granted, now 10,464,997, previously published as PCT/US2015/015369, filed on Feb. 11, 2015.
Claims priority of provisional application 61/938,378, filed on Feb. 11, 2014.
Prior Publication US 2020/0115438 A1, Apr. 16, 2020
Int. Cl. C07K 16/00 (2006.01); A61K 47/68 (2017.01); C07K 1/36 (2006.01); C07K 1/08 (2006.01); C07K 1/113 (2006.01)
CPC C07K 16/00 (2013.01) [A61K 47/68 (2017.08); A61K 47/6817 (2017.08); A61K 47/6889 (2017.08); C07K 1/086 (2013.01); C07K 1/1133 (2013.01); C07K 1/36 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01)] 14 Claims
 
1. A method for selective activation of engineered cysteine residues of engineered cysteine antibodies, said method comprising:
(a) diafiltering a mixture of engineered cysteine antibodies and buffer, and
(b) adding a reducing agent to said mixture in a concentration and at a rate to activate a portion of available engineered cysteine residues while retaining at least 80% of all inter-chain disulfide bonds present in the engineered cysteine antibodies prior to (b); and
(c) maintaining diafiltration of said mixture during step (b);
to selectively activate the engineered cysteine residues.